<DOC>
	<DOCNO>NCT02440620</DOCNO>
	<brief_summary>This study describe epidemiology include prognosis heart failure relate treatment anthracycline trastuzumab breast cancer . In prospective study Human Epidermal Growth Factor Receptor 2 ( HER2 ) positive breast cancer patient schedule trastuzumab treatment Odense University Hospital , offer advanced echocardiographic examination , test bio-markers genetic marker purpose investigate early identification patient particular risk develop heart failure feasible .</brief_summary>
	<brief_title>Cardiac Toxicity Medical Treatment Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Diagnosis HER2 positive breast cancer Adjuvant treatment trastuzumab Left ventricle ejection fraction ( LVEF ) &lt; 50 % Chronic persistent atrial fibrillation History moderate severe valvular heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Heart failure relate medical treatment breast cancer</keyword>
</DOC>